GLP-1R Signaling Linked to Reduced Psoriasis Risk in Genetic Study

Emerging interest in glucagon-like peptide-1 receptor (GLP-1R) agonists—widely used in type 2 diabetes and obesity—has prompted investigation into their potential role in inflammatory skin disease.¹ A recently published Mendelian randomization (MR) analysis provides new genetic evidence suggesting that increased GLP-1R expression may reduce susceptibility to both psoriasis and psoriatic arthritis (PsA), offering insight into a potentially novel therapeutic pathway.²

MORE ON PSORIASIS

Study Design and Approach

The investigators employed a target-focused MR framework, leveraging genetic variants associated with GLP-1R expression as instrumental variables to infer causal relationships with disease risk. This approach minimizes confounding and reverse causation, common limitations of observational studies.

Genetic proxies were derived from cis-expression quantitative trait loci (eQTLs) for GLP-1R in whole blood. These were analyzed against large genome-wide association study (GWAS) datasets, including more than 36,000 psoriasis cases and over 5,000 PsA cases of European ancestry.

To contextualize findings, the authors incorporated cardiometabolic traits—such as body mass index (BMI), lipid levels, type 2 diabetes, and coronary artery disease—as positive controls, given their known responsiveness to GLP-1R agonist therapy.

Key Findings in Psoriasis and PsA

Genetically proxied increases in GLP-1R expression were associated with significantly lower risk of psoriasis (odds ratio [OR] 0.72, 95% CI 0.68–0.77) and PsA (OR 0.48, 95% CI 0.40–0.58).

Importantly, these associations persisted after adjustment for metabolic traits in multivariable MR models, although attenuated for psoriasis (OR 0.86). The persistence of effect suggests that the observed protective relationship is not solely mediated through weight loss or metabolic improvement.

Sensitivity analyses using alternative MR methods yielded consistent directional results, supporting the robustness of the findings and reducing the likelihood that pleiotropy explains the associations.

Disease Specificity Across Immune-Mediated Conditions

To explore whether this relationship extended to other immune-mediated inflammatory diseases (IMIDs), the authors evaluated several conditions, including eczema, asthma, multiple sclerosis, inflammatory bowel disease, and rheumatoid arthritis (RA).

No association was observed for several IMIDs, including eczema and asthma. However, in contrast to psoriasis, increased GLP-1R expression was associated with higher risk of Crohn’s disease (OR 1.24) and RA (OR 1.50).

These divergent findings suggest that GLP-1 pathway effects may be disease-specific rather than broadly anti-inflammatory across immune-mediated conditions.

Biological Plausibility

The results align with emerging mechanistic data. GLP-1 receptors are expressed in keratinocytes, endothelial cells, and immune cells implicated in psoriasis pathogenesis. GLP-1 signaling has been shown to influence innate immune responses and inflammatory pathways, providing a plausible biological basis for the observed associations.

Clinically, small randomized and observational studies have reported improvements in psoriasis severity among patients treated with GLP-1R agonists. However, these studies have been limited by small sample sizes and potential confounding from weight loss.

The current genetic analysis strengthens the argument for a direct immunomodulatory role, independent of metabolic effects.

Limitations and Interpretation

Several limitations warrant consideration. MR reflects the impact of lifelong genetic variation rather than short-term pharmacologic intervention, and therefore may not fully capture the effects of GLP-1R agonist therapy in clinical practice.

Additionally, analyses were restricted to individuals of European ancestry, potentially limiting generalizability.

Colocalization analyses did not provide definitive evidence of a shared causal variant between GLP-1R expression and psoriatic disease risk, and results were sensitive to prior assumptions. As such, the findings should be interpreted as supportive rather than conclusive evidence of causality.

Clinical Implications

These findings contribute to a growing body of evidence suggesting that GLP-1R signaling may play a role in psoriatic disease biology. While GLP-1R agonists are not currently indicated for psoriasis, the genetic data provide a rationale for further mechanistic studies and clinical trials to evaluate their potential as adjunctive or disease-modifying therapies.

At the same time, the observed heterogeneity across IMIDs underscores the need for disease-specific evaluation. The increased genetic risk observed in Crohn’s disease and RA highlights that modulation of the GLP-1 pathway may have complex and context-dependent immune effects.

Conclusion

This MR analysis suggests that increased GLP-1R expression is associated with reduced risk of psoriasis and PsA, independent of metabolic pathways. Although further clinical validation is needed, these findings support continued investigation into GLP-1–based therapies as a potential avenue in psoriatic disease management.

MORE ON GLP-1s FROM OUR RECENT PRINT ISSUE

References

1. Mariam Z, Niazi SK. Glucagon-like peptide agonists: A prospective review. Endocrinol Diabetes Metab. 2024;7(1):e462. doi:10.1002/edm2.462
2. Ramessur R, Arham AGA, Saklatvala J, et al. Genetic proxies of GLP1R expression are associated with lower risk of psoriasis and psoriatic arthritis. Br J Dermatol. 2026. doi:10.1093/bjd/ljag163